- Home
- GLRE vs DCTH Comparison
GLRE vs DCTH Comparison
Compare GLRE & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLRE
- DCTH
- Stock Information
- Founded
- GLRE 2004
- DCTH 1988
- Country
- GLRE Cayman Islands
- DCTH United States
- Employees
- GLRE N/A
- DCTH N/A
- Industry
- GLRE Property-Casualty Insurers
- DCTH Medical/Dental Instruments
- Sector
- GLRE Finance
- DCTH Health Care
- Exchange
- GLRE Nasdaq
- DCTH Nasdaq
- Market Cap
- GLRE 439.8M
- DCTH 388.3M
- IPO Year
- GLRE 2007
- DCTH N/A
- Fundamental
- Price
- GLRE $12.93
- DCTH $8.66
- Analyst Decision
- GLRE
- DCTH Strong Buy
- Analyst Count
- GLRE 0
- DCTH 5
- Target Price
- GLRE N/A
- DCTH $22.60
- AVG Volume (30 Days)
- GLRE 127.7K
- DCTH 1.1M
- Earning Date
- GLRE 11-03-2025
- DCTH 11-04-2025
- Dividend Yield
- GLRE N/A
- DCTH N/A
- EPS Growth
- GLRE N/A
- DCTH N/A
- EPS
- GLRE N/A
- DCTH 0.03
- Revenue
- GLRE $661,540,000.00
- DCTH $79,603,000.00
- Revenue This Year
- GLRE N/A
- DCTH $135.11
- Revenue Next Year
- GLRE N/A
- DCTH $36.30
- P/E Ratio
- GLRE N/A
- DCTH $251.41
- Revenue Growth
- GLRE N/A
- DCTH 251.54
- 52 Week Low
- GLRE $11.57
- DCTH $8.33
- 52 Week High
- GLRE $15.38
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- GLRE 56.99
- DCTH 35.08
- Support Level
- GLRE $11.57
- DCTH $8.33
- Resistance Level
- GLRE $13.35
- DCTH $9.19
- Average True Range (ATR)
- GLRE 0.34
- DCTH 0.50
- MACD
- GLRE 0.08
- DCTH -0.00
- Stochastic Oscillator
- GLRE 79.83
- DCTH 18.54
About GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.